Therapy of small cell lung cancer with emphasis on oral topotecan

被引：12

作者：

Pirker, Robert ^{[1
]}

Berzinec, Peter ^{[2
]}

Brincat, Stephen ^{[3
]}

Kasan, Peter ^{[4
]}

Ostoros, Gyula ^{[5
]}

Pesek, Milos ^{[6
]}

Plate, Signe ^{[7
]}

Purkalne, Gunta ^{[8
]}

Rooneem, Regina ^{[9
]}

Skrickova, Jana ^{[10
]}

Stanculeanu, Dana ^{[11
]}

Timcheva, Constanta ^{[12
]}

Tzekova, Valentina ^{[13
]}

Zakotnik, Branko ^{[14
]}

Zielinski, Christoph C. ^{[1
]}

Zwitter, Matjaz ^{[15
]}

机构：

[1] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria

[2] Specialised Hosp St Zoerardus Zobor, Dept Oncol, Nitra, Slovakia

[3] Sir Paul Boffa Hosp, Floriana, Malta

[4] Univ Hosp Bratislava, Dept Oncol, Bratislava, Slovakia

[5] Natl Koranyi Inst TB & Pulmonol, Budapest, Hungary

[6] Charles Univ Prague, Fac Med, Plzen, Czech Republic

[7] Riga Easten Univ Hosp, Riga, Latvia

[8] Paul Stradins Clin Univ Hosp Riga, Radiat & Chemotherapy Ctr, Riga, Latvia

[9] N Estonia Reg Hosp, Ctr Canc, Dept Chemotherapy, Tallinn, Estonia

[10] Univ Hosp, Dept Resp Dis & TB, Brno, Czech Republic

[11] Inst Oncol, Bucharest, Romania

[12] Specialized Hosp Active Treatment Oncol, Sofia, Bulgaria

[13] ISUL, Univ Hosp Queen Joanna, Clin Chemotherapy, Sofia, Bulgaria

[14] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia

[15] Inst Oncol Ljubljana, Dept Radiat Oncol, Ljubljana, Slovenia

来源：

LUNG CANCER | 2010年 / 70卷 / 01期

关键词：

Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan; PROPHYLACTIC CRANIAL IRRADIATION; PREVIOUSLY UNTREATED PATIENTS; CISPLATIN PLUS ETOPOSIDE; LONG-TERM SURVIVAL; PHASE-III TRIAL; PROGNOSTIC-FACTORS; THORACIC RADIOTHERAPY; 2ND-LINE TREATMENT; CHEMOTHERAPY; AMRUBICIN;

D O I：

10.1016/j.lungcan.2010.05.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：7 / 13

页数：7

共 50 条

[41] Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer
Garst, Jennifer
EXPERT OPINION ON DRUG SAFETY, 2007, 6 (01) : 53 - 62
[42] Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer
von Pawel, J
Gatzemeier, U
Pujol, JL
Moreau, L
Bildat, S
Ranson, M
Richardson, G
Steppert, C
Rivière, A
Camlett, I
Lane, S
Ross, G
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1743 - 1749
[43] Clinical experience with oral topotecan in relapsed small cell lung cancer patients following irinotecan-platinum chemotherapy
Behera, D.
Maturu, V. N.
Sehgal, I. S.
Singh, N.
LUNG CANCER, 2015, 87 : S58 - S58
[44] Topotecan active as first-line combination therapy for advanced non-small-cell lung cancer
不详
ONCOLOGY-NEW YORK, 2001, 15 (02): : 186 - +
[45] Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer
Desai, Parth Anil
Takahashi, Nobuyuki
Lissa, Delphine
Nichols, Samantha
Sciuto, Linda
Abel, Melissa Lauren
Schroeder, Brett
Schultz, Christopher
Steinberg, Seth M.
Pinkiert, Danielle
Vilimas, Rasa J.
Thomas, Anish
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] New outlook for the treatment of small-cell lung cancer: The role of topotecan
Frasci, G
TUMORI, 1997, 83 (06) : S15 - S23
[47] Phase I Study of Topotecan and Cisplatin in Patients with Small Cell Lung Cancer
Ichinose, Yukito
Seto, Takashi
Nishiwaki, Yutaka
Kiura, Katsuyuki
Sakai, Hiroshi
Yokoyama, Akira
Segawa, Yoshihiko
Ando, Masahiro
Watanabe, Koshiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 197 - 203
[48] Topotecan for relapsed small cell lung cancer: A systematic review and economic evaluation
Hartwell, Debbie
Jones, Jeremy
Loveman, Emma
Harris, Petra
Clegg, Andrew
Bird, Alex
CANCER TREATMENT REVIEWS, 2011, 37 (03) : 242 - 249
[49] Topotecan every 28 days in refractory or relapsed small cell lung cancer
Safont, M
Berrocal, A
Martinez, N
Camps, C
Blasco, A
Garde, J
Gavila, Q
Juarez, A
Iranzo, V
Sirera, R
LUNG CANCER, 2005, 49 : S327 - S327
[50] Topotecan in the first-line treatment of small-cell lung cancer
Wolf, M
ONKOLOGIE, 2000, 23 : 13 - 17

← 1 2 3 4 5 →